Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cells

Cancer Gene Therapy

Volumn 6, Issue 1, 1999, Pages 37-44

  Visse, Edward ^a   Siesjö, Peter ^a   Widegren, Bengt ^a   Sjögren, Hans Olov ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

B7 1; Immunotherapy; Interferon ; Interleukin 7; Rat brain tumor

Indexed keywords

ANTIBIOTIC G 418; ANTIINFECTIVE AGENT; B7 ANTIGEN; GAMMA INTERFERON; GENTAMICIN; INTERLEUKIN 7;

ANIMAL; ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; GLIOMA; IMMUNOTHERAPY; MALE; RAT; SEX DIFFERENCE; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, CD80; BRAIN NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENTAMICINS; GLIOMA; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-7; MALE; RATS; SEX FACTORS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032618857     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700023     Document Type: Article

References (54)

1. Garrido F, Klein E, eds. MHC Antigen Expression I: Human Tumors. Philadelphia: Saunders Science Publications; 1991.
2. Garrido F, Klein E, eds. MHC Antigen Expression II: Experimental Systems. Philadelphia: Saunders Science Publications; 1991.
3. Tanaka K, Hayashi H, Hamada C, et al. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA. 1986;83:8723-8727.
4. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
5. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421-428.
6. Aoki T, Tashiro K, Miyatake S-I, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA. 1992;89:3850-3854.
7. Nishihara K. A novel experimental approach to immunotherapy against malignant brain tumor with mouse IFN-γ gene transfer. Arch Jpn Chir. 1989;58:18-42.
8. Li Y, Hellström KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med. 1996;183:639-644.
9. Yang G, Hellström KE, Hellström I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol. 1995;154:2794-2800.
10. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
11. McBride WH, Thacker JD, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 1992;52:3931-3937.
12. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
13. Matory YL, Chen M, Dorfman DM, et al. Antitumor activity of three mouse mammary cancer cell lines after interferon-γ gene transfection. Surgery. 1995;118:251-256.
14. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 1995:399-415.
15. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
16. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-β in glioblastoma: preferential production of transforming growth factor-β2. J Immunol. 1989; 143:3222-3229.
17. Wekerle H, Engelhardt B, Risau W, Meyerman R. Passage of lymphocytes across the blood-brain barrier in health and disease. In: Johansson B, Owman C, Widner H, eds. Pathophysiology of the Blood-Brain Barrier. Amsterdam: Elsevier Science Publishers; 1990:439-445.
18. de Micco C, Hassoun J, Meyer G, Toga M. Role of the blood-brain barrier in the establishment of the immune response against polyoma virus-induced cerebral tumors in hamsters. J Neuroimmunol. 1986;11:301-310.
19. Greig NH, Jones HB, Cavanagh JB. Blood-brain barrier integrity and host responses in experimental metastatic brain tumors. Clin Exp Metastasis. 1983;1:229-246.
20. + T cell lines in vitro. J Immunol. 1990;145:2474-2481.
21. Kojima K, Berger T, Lassmann H, et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100-β molecule, a calcium binding protein of astroglia. J Exp Med. 1994;180:817-829.
22. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA. 1996;93:2909-2914.
23. Holladay FP, Heitz T, Chen YL, et al. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery. 1992;31:528-533.
24. Yumitori K, Ito Y, Handa H. Protective effect of immunization with virus-infected glioma cells against intracerebrally implanted glioma in mice. Eur J Cancer Clin Oncol. 1982;18:177-182.
25. Siesjö P, Visse E, Sjögren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment. J Immunother Emphasis Tumor Immunol. 1996;19:334-345.
26. Siesjö P, Visse E, Lindvall M, et al. Immunization with mutagen-treated tumor cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother. 1993;37:67-74.
27. Markowitz D, Bank SGA. A safe packaging line for gene transfer separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
28. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-569.
29. Stephenson KR, Perry-Lalley D, Griffith KD, et al. Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery. 1989;105:523-528.
30. + rat glioma. Cell Immunol. 1995;165: 225-233.
31. Young HA, Hardy KJ. Role of interferon-γ in immune cell regulation. J Leukoc Biol. 1995;58:373-381.
32. Anderson SL, Shen T, Lou J, et al. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J Exp Med. 1994;180:1565-1569.
33. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994;180:1367-1374.
34. Di Marzio P, Puddu P, Conti L, et al. Interferon γ upregulatcs its own gene expression in mouse peritoneal macrophages. J Exp Med. 1994;179:1731-1736.
35. Gabathuler R, Reid G, Kolaitis G, et al. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med. 1994;180:1415-1425.
36. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro: contribution to inhibitory action of interferon-γ and tumor necrosis factor-α. J Clin Invest. 1995;96:1085-1092.
37. O'Garra A, Murphy K. T-cell subsets in autoimmunity. Cuir Opin Immunol. 1993;5:880-886.
38. Openshaw P, Murphy EE, Hosken NA, et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med. 1995;182:1357-1367.
39. + Tc1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med. 1995;182:1505-1515.
40. Flesch IEA, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis factor α. J Exp Med. 1995;181:1615-1621.
41. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant.' Science. 1991;252:854-855.
42. Watanabe Y. Transfection of interferon-γ gene in animal tumors: a model for local cytokine production and tumor immunity. Semin Cancer Biol. 1992;3:43-46.
43. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: eifects of IL-2 dose on anti-tumor immunity. Hum Gene Ther. 1995;6:591-601.
44. Porgador A, Gansbacher B, Bannerji R, et al. Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer. 1993;53:471-477.
45. Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin 2: increased sensitivity after MHC class I gene transfection. J Exp Med. 1987;166:1716-1733.
46. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994;179:1215-1224.
47. Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med. 1994;179:31-42.
48. Satoskar A, Alexander J. Sex-determined susceptibility and differential IFN-γ and TNF-α mRNA expression in DBA-2 mice infected with Leishmania mexicana. Immunology. 1995;84:1-4.
49. Grossman C. Possible underlying mechanisms of sexual dimorphism in the immune response fact and hypothesis. J Steroid Biochem. 1989;34:241-252.
50. Viselli SM, Stanziale S, Shults K, et al. Castration alters peripheral immune function in normal male mice. Immunology. 1995;84:337-342.
51. Araneo BA, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and γ interferon, but not IL-2 by activated murine T cells. Blood. 1991;78:688-699.
52. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-γ promoter. J Immunol. 1991;146:4362-4367.
53. Zuckerman SH, Bryan-Poole N, Evans GF, et al. In vivo modulation of murine serum tumor necrosis factor and interleukin-6 levels during endotoxemia by estrogen agonists and antagonists. Immunol. 1995;86:18-24.
54. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156-1159.